Compare ARDX & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | IMTX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | IMTX |
|---|---|---|
| Price | $5.12 | $9.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $15.14 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 4.7M | 345.9K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $37.75 | N/A |
| Revenue Next Year | $34.24 | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.08 | $5.05 |
| 52 Week High | $8.40 | $12.41 |
| Indicator | ARDX | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.21 | 41.39 |
| Support Level | $4.89 | $8.98 |
| Resistance Level | $5.34 | $10.67 |
| Average True Range (ATR) | 0.21 | 0.52 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 30.40 | 7.84 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.